Egetis Financial Statements From 2010 to 2024
| EGTX Stock | SEK 5.41 0.19 3.39% |
Check Egetis Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Egetis Therapeutics' main balance sheet or income statement drivers, such as , as well as many indicators such as . Egetis financial statements analysis is a perfect complement when working with Egetis Therapeutics Valuation or Volatility modules.
Egetis |
Egetis Therapeutics AB Company Current Valuation Analysis
Egetis Therapeutics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Egetis Therapeutics Current Valuation | 698.73 M |
Most of Egetis Therapeutics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Egetis Therapeutics AB is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Egetis Therapeutics AB has a Current Valuation of 698.73 M. This is 95.14% lower than that of the Healthcare sector and 84.96% lower than that of the Biotechnology industry. The current valuation for all Sweden stocks is 95.8% higher than that of the company.
Egetis Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Egetis Therapeutics's current stock value. Our valuation model uses many indicators to compare Egetis Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Egetis Therapeutics competition to find correlations between indicators driving Egetis Therapeutics's intrinsic value. More Info.Egetis Therapeutics AB is rated # 2 in return on equity category among its peers. It also is rated # 2 in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Egetis Therapeutics' earnings, one of the primary drivers of an investment's value.About Egetis Therapeutics Financial Statements
Egetis Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Egetis Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Egetis Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Egetis Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Egetis Therapeutics AB , a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rareniche diseases with unmet medical needs in the orphan drug segment. Egetis Therapeutics AB was founded in 2006 and is based in Stockholm, Sweden. Egetis Therapeutics operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 11 people.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Egetis Stock Analysis
When running Egetis Therapeutics' price analysis, check to measure Egetis Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Egetis Therapeutics is operating at the current time. Most of Egetis Therapeutics' value examination focuses on studying past and present price action to predict the probability of Egetis Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Egetis Therapeutics' price. Additionally, you may evaluate how the addition of Egetis Therapeutics to your portfolios can decrease your overall portfolio volatility.